A Randomized Double-Blind Placebo-Controlled Parallel-Group Study Conducted Under In-House Blinding Conditions of MK0633 in Patients With COPD.

Trial Profile

A Randomized Double-Blind Placebo-Controlled Parallel-Group Study Conducted Under In-House Blinding Conditions of MK0633 in Patients With COPD.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Setileuton (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2009 Actual patient number changed from 380 to 266 as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual patient number (380) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top